GlassScriptPhysician profile
Ronald Coleman
NPI 1841304540
$1,900.48
in general payments reported to CMS, 2019-2025
26 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $15.29 · 2022: $194 · 2023: $16.92 · 2024: $425 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $334.62 | 2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $293.84 | 2024-2025 | |
| Novo Nordisk INC | $167.37 | 2022 | |
| Pfizer INC. | $146.11 | 2019-2025 | |
| Janssen Biotech, INC. | $142.49 | 2025 | Tremfya |
| Johnson & Johnson Health Care Systems INC. | $142.47 | 2024 | Tremfya |
| Collegium Pharmaceutical, INC. | $77.81 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $74.94 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $70.87 | 2024-2025 | Azstarys |
| Tris Pharma INC | $64.32 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $51.62 | 2024 | |
| Glaxosmithkline, LLC. | $42.21 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Organon LLC | $30.78 | 2025 | Nexplanon |
| Kyowa Kirin, INC. | $28.77 | 2025 | |
| Medtronic, INC. | $26.78 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $24.93 | 2025 | Neffy |
| Cipher Pharmaceuticals US LLC | $22.38 | 2025 | Natroba, Spinosad |
| Inspire Medical Systems, INC. | $20.10 | 2024 | Inspire |
| Daiichi Sankyo INC. | $19.26 | 2019 | |
| Olympus America INC. | $19.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.06 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $18.91 | 2025 | Voquezna |
| Dexcom, INC. | $16.92 | 2023 | Dexcom G6 Transmitter |
| Vertical Pharmaceuticals, LLC | $15.40 | 2025 | Relexxii |
| Otsuka America Pharmaceutical, INC. | $15.29 | 2020 | |
| Cranial Technologies, INC | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.